1 |
CNR1
| [4] Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D10915
D10915
|
Cannabidiol
| [19] 2 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
2 |
CNR2
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10915
D10915
|
Cannabidiol
| [10] 140 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
3 |
DDC
| [9] Tyrosine metabolism Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism | D00558
D00558
|
Carbidopa
| [9] 2 2, 4, 6, 13, 17, 90, 140, 164, 201 |
4 |
DRD1
| [10] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D00059
D00059
|
Levodopa
| [8] 2 2, 4, 6, 17, 90, 140, 164, 201 |
5 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00059
D00059
|
Levodopa
| [8] 2 2, 4, 6, 17, 90, 140, 164, 201 |
6 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| [8] 2 2, 4, 6, 17, 90, 140, 164, 201 |
7 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| [8] 2 2, 4, 6, 17, 90, 140, 164, 201 |
8 |
DRD5
| [4] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00059
D00059
|
Levodopa
| [8] 2 2, 4, 6, 17, 90, 140, 164, 201 |
9 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
10 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
11 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
12 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
13 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
14 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
15 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
16 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
17 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
18 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
19 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
20 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
21 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
22 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
23 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
24 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
25 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
26 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
27 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
28 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
29 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
30 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
31 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
32 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
33 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
34 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
35 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
36 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
37 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
38 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
39 |
GRIA1
| [14] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
40 |
GRIA2
| [15] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
41 |
GRIA3
| [13] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
42 |
GRIA4
| [10] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
43 |
GRIK1
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
44 |
GRIK2
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
45 |
GRIK3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
46 |
GRIK4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
47 |
GRIK5
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
48 |
HTR2A
| [5] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D07945
D07945
|
Fenfluramine
| [4] 140 140, 144, 145, 149 |
49 |
HTR2B
| [5] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D07945
D07945
|
Fenfluramine
| [4] 140 140, 144, 145, 149 |
50 |
HTR2C
| [5] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels | D07945
D07945
|
Fenfluramine
| [4] 140 140, 144, 145, 149 |
51 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
52 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D01253
D01253
|
Clobazam
| [2] 140 140, 144 |
53 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D00537
D00537
|
Topiramate
| [4] 140 140, 144, 156, 193 |
54 |
SCN2A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [4] 140 140, 144, 156, 193 |
55 |
SCN3A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [4] 140 140, 144, 156, 193 |
56 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00537
D00537
|
Topiramate
| [4] 140 140, 144, 156, 193 |
57 |
SCN9A
| [1] Taste transduction Taste transduction | D00537
D00537
|
Topiramate
| [4] 140 140, 144, 156, 193 |
58 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07945
D07945
|
Fenfluramine
| [4] 140 140, 144, 145, 149 |
59 |
CA2
| [7] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
60 |
CA4
| [3] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
61 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
62 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00619
D00619
|
Verapamil
| [3] 96 96, 140, 167 |
63 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [3] 96 96, 140, 167 |
64 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
65 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00619
D00619
|
Verapamil
| [3] 96 96, 140, 167 |
66 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [3] 96 96, 140, 167 |
67 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
68 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00619
D00619
|
Verapamil
| [3] 96 96, 140, 167 |
69 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [3] 96 96, 140, 167 |
70 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| [6] 6 6, 97, 140, 144, 156, 193 |
71 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00619
D00619
|
Verapamil
| [3] 96 96, 140, 167 |
72 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [3] 96 96, 140, 167 |